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ABSTRACT  
Background: Cases of fever without diagnoses of malaria and/or typhoid are usually 
regarded as undifferentiated febrile illness (UFI) in Nigeria. We studied the contribution of 
WNV (an arbovirus) to UFI in humans in southwestern Nigeria.  
Materials and methods: Sera from 188 consenting humans visiting two health care facilities 
in Ibadan, and 25 horse grooms from Lagos and Ibadan were screened for WNV antibodies 
by cELISA and a subset by PRNT. Pertinent demographic/clinical data were collected and 
blood samples screened for Plasmodium spp, Salmonella typhi and S. paratyphi antibodies. 
Student’s t-test and binary logistic regression were used for data analysis.  
Results: Overall, 156 participants (73.2%, 95% CI: 67.3-79.2 [n=213]) were positive for 
WNV antibodies. Being clinically ill was associated (p=0.001) with WNV seropositivity 
while “active” and “non-active” participants had comparable (p=0.21) seroprevalence of 
74.6% and 62.5%, respectively. Forty-five percent (18/40) of febrile participants had WNV 
antibodies only, thereby accounting for UFI. The 18-66 year olds had higher (75.8%) 
seroprevalence than those  17 years (47.4%) while seropositivity obtained for the horse 
grooms (56.0%) was significantly lower than for the remaining 188 individuals (75.5%). 
Participants were mostly exposed to WNV (75.5%) than Plasmodium (33.5%) and S. typhi 
(39.9%) while PRNT showed that 10.5% of tested humans had protective WNV antibodies.  
Conclusions: This study revealed serologic evidence of exposure of the participants to WNV 
and contribution of the virus (or related flaviviruses) to UFI in the study area. High 
prevalence of the antibodies indicates endemicity of southwestern Nigeria for WNV.  
Key words: Humans, anti-WNV antibody, prevalence rate, undifferentiated febrile illness, 
southwestern Nigeria. 
est Nile virus (WNV) is a 
neurovirulent, zoonotic 
mosquito-borne virus belonging 
to the genus Flavivirus in the family 
Flaviviridae; it is responsible for outbreaks 
of meningitis and encephalitis1.  The virus 
is maintained in an enzootic cycle between 
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ornithophilic mosquitoes and birds, but 
can also infect and cause disease in horses 
and humans2. In humans, infection begins 
following a bite from a WNV-infected 
female mosquito (e.g. Culex mosquito)3. 
WNV was regarded as a mild pathogen 
causing self-limiting outbreaks but this 
notion changed when the virus caused 
large epidemics with high impact on 
human and animal health, hence it has 
been termed a re-emerging zoonotic 
pathogen4. Recently, the geographic range 
of WNV has been extended to all 
continents of the world with significant 
increase in incidence in humans, horses 
and birds5. The virus is found in Africa, 
Asia and Europe, the Mediterranean 
region, the Middle East, Australia and the 
W 
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Americas6, 7. It was first isolated from a 37 
year-old febrile woman in the West Nile 
District of northern Uganda in 19378.  The 
first reported human epidemic occurred in 
Israel in 1951, and the first isolation of 
WNV from Culex mosquito was made in 
19529. Epidemics of WNV infection in 
humans have occurred in Algeria, 
Romania, Russia and South Africa10, 11, 12, 
13.  Occurrence of WNV in mosquitoes and 
detection of specific antibodies in febrile 
patients have been documented in northern 
Nigeria14, 15.  
Surveillance for WNV activity in any 
population can be achieved through 
seroprevalence study. Hence, animals such 
as camels, goats, cattle, sheep and horses 
in Nigeria and Romania have been 
reported as having hemagglutination-
inhibiting antibodies to WNV10, 11, 16, 17. 
Plaque reduction neutralization test 
(PRNT) has also been used for sero-
surveillance in the USA and Nigeria14, 15, 18 
and for determination of correlate of sero-
protection19. 
Nigeria is endemic for malaria and typhoid 
fevers. Hence, many cases of febrile 
illness are usually regarded by physicians 
as either of these diseases15, 21. Also, when 
malaria and typhoid tests are negative for a 
given patient, such cases are commonly 
regarded as “undifferentiated febrile 
illness (UFI)” especially when the patients 
fail to respond to anti-malarial drugs17. 
Since most health facilities in Nigeria lack 
the capacity to conduct arboviral 
investigations on such “UFI” patients, 
physicians treat them symptomatically.  
In an earlier study of horses in 
southwestern Nigeria, high WNV antibody 
prevalence was reported with 
establishment of enzootic status among the 
horses22. It is therefore necessary to test 
the humans and grooms in daily contact 
with horses for evidence of exposure to 
WNV. Association of WNV with cases of 
UFI has only been reported in two studies 
from northern Nigeria14, 15 and, to our 
knowledge, evidence of WNV infection in 
humans has not been reported in 
southwestern Nigeria in recent years. We 
therefore hypothesized that WNV 
infection has no association with febrile 
illness in humans in southwestern Nigeria 
and that humans in this region have no 
evidence of exposure to the virus. 
MATERIALS AND METHODS: 
Description of human participants and 
locations: 
This study was conducted between June, 
2011 and October, 2012. The human 
participants in this study were resident in 
Ibadan, Oyo state, and Onosa and Ajah, 
Lagos state, southwestern Nigeria. They 
were mostly Yorubas of male and female 
genders. The participants largely 
comprised two groups: a group that visited 
healthcare facilities for medical test or 
medical care while the other group 
consisted of horse grooms who handled 
and took care of horses in their stables or 
polo clubs. The participants visited two 
different healthcare facilities, namely the 
Central Medical Diagnostic Center 
(CMDC), Total Garden, Ibadan 
(N07.398°, E003.910°) and Department of 
Family Medicine, University College 
Hospital (UCH), Ibadan (N07.4015°, 
E003.90345°). Those from CMDC were 
apparently healthy referral patients from 
Adeoyo State Hospital, Ibadan which 
provides medical care to mostly residents 
of Ibadan who visit the laboratory for tests 
ranging from pregnancy to malaria parasite 
(MP) and Widal (for typhoid fever), 
among others. The humans from UCH, 
which is a tertiary healthcare facility that 
provides medical services majorly to 
patients from southwestern Nigeria, other 
parts of the country and neighboring 
countries, comprised apparently healthy 
and clinically ill participants. The horse 
grooms were all males, apparently healthy 
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and mostly of Hausa extraction with few 
Yorubas. They belonged to the Eleyele 
Polo club (N06.4500°, E003.4333°), 
Ibadan, and the Onosa (N06.47001°, 
E003.80226°) and Ajah (N06.46700°, 
E003.57255°) horse ranches. They groom 
and exercise the horses daily, and 
accompany them to various locations in 
Nigeria for annual polo tournaments. Oyo 
and Lagos states are located in the tropical 
rainforest in southwestern Nigeria and 
enjoy wet season from April/May to 
October/November and dry season from 
November to March/April.  
Study design and sample size: 
This is a cross-sectional serosurvey of 
individuals from CMDC and UCH, and 
horse grooms from Eleyele polo club, 
Ibadan and horse ranches in Lagos. Only 
humans who completed consent forms 
were consecutively included in this study. 
With the assistance of physicians, 
pertinent demographic and clinical data 
were obtained from participants in UCH; 
these include fever, headache, 
muscular/joint pains and abdominal 
pains/discomfort. Being basically a 
diagnostic laboratory, there was no 
physician at CMDC, and it was not 
logistically possible to employ the services 
of one at the Centre. Hence, some clinical 
data were not obtained for the CMDC 
cohort. 
In order to establish contribution of WNV 
infection to UFI among participants, the 
blood and serum samples of participants 
from UCH and CMDC were subjected to 
malaria parasite and Widal tests as well as 
WNV antibody detection ELISAs. 
However, the horse grooms were only 
tested for WNV antibodies. 
Using the formula for estimating sample 
size23, 24, and 80.16% prevalence rate of 
WNV antibody in humans of northern 
Nigeria14, a sample size of 246 humans 
was arrived at. However, for logistic 
reasons, we could only study 213 human 
participants.                                         
Blood sample collection, serum 
preparation and storage: 
About 7ml blood sample was aseptically 
collected by a phlebotomist from each 
participant via venepuncture. At UCH, 1ml 
of the collected blood was dispensed into 
clean EDTA-treated vial and sent to the 
Medical Microbiology and Parasitology 
laboratory for MP test while 2ml blood 
was dispensed into labeled anti-coagulant-
free Universal bottle and screened for the 
presence of anti-O and anti-H antibodies 
against Salmonella typhi, and S. paratyphi 
A, B and C by the Widal agglutination test 
the same day. The MP and Widal tests 
were also done at CMDC. Sera prepared 
from each of the remaining blood samples 
were appropriately labeled and stored at -
80°C until assayed for WNV antibodies. 
The remaining blood samples left to clot at 
room temperature were spun at 3,000 rpm 
for 10 minutes. The supernatant (serum) 
from each sample was collected with a 
new Pasteur pipette into appropriately 
labeled Eppendorf tubes and stored at -
80°C until tested for WNV antibodies in 
the Virology laboratory, Department of 
Veterinary Microbiology and Parasitology, 
University of Ibadan. 
Inclusion criteria for the study were male 
and female patients of all ages 
with/without fever, headache and 
muscular/joint pains with or without 
neurologic signs, and willingness to 
provide samples for MP and Widal tests 
while exclusion criterion was 
unwillingness of patients to participate in 
the study. 
Malaria parasite test for detection of 
Plasmodium species: 
Within one hour of blood sample 
collection and using established protocol21, 
25, separate thick and thin blood films were 
made from each blood sample on clean 
glass slides, labeled accordingly and 
examined by microscopy. The blood 
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samples were handled carefully as 
potentially infectious. 
Widal slide agglutination assay: 
Each serum sample was subjected to 
Widal slide agglutination test for detection 
of anti-O and -H antibodies against S.
typhi, and S. paratyphi A, B and C using 
the rapid Cromatest® Febrile Antigen Kit 
(LINEAR CHEMICALS S.L., Barcelona, 
Spain) according to manufacturer’s 
instruction. When the rapid slide 
agglutination test was positive for any 
sample, it was further confirmed by tube 
agglutination test as described by Opara et
al.21. A serum sample was considered 
positive when it produced visible 
agglutination at  1:80 dilution for O 
antigen and  1:160 for H antigen. When a 
sample gave agglutination at 1:40 dilution 
for only one of the eight antigens, the test 
was repeated.  
Enzyme-linked immunosorbent assay 
(ELISA) for detection of WNV 
antibodies: 
Prior to performing the ELISA on human 
sera, individual serum sample was spotted 
in two replicates on Whatman FTA® card 
and appropriately labeled. Punched-out 
discs were soaked in elution buffer and the 
RNA eluted from the cards was subjected 
to real-time RT-PCR using WNV-specific 
primers and probes to detect WNV RNA 
(as evidence of viraemia). Since none of 
the tested sera had detectable WNV RNA, 
they were therefore tested for only WNV 
IgG antibodies using West Nile Virus 
Antibodies Enzyme Immunoassay (DIA. 
PRO, Diagnostic Bioprobes Srl Via G, 
Milano, Italy) for qualitative determination 
of antibodies to WNV in human serum. 
The assay was done according to 
manufacturer’s instructions.  
Plaque reduction neutralization test 
(PRNT): 
Two-fold serial dilutions of test, and 
positive and negative control sera were 
incubated for about 60 minutes with equal 
volume of virus at 37°C in 5% CO2. The 
respective serum-virus mixtures were 
incubated with about 2-day-old confluent 
Vero C1008 cells in twelve-well tissue 
culture plates for 60 minutes at 37°C and 
5% CO2 along with wells containing virus-
only and medium-only controls. Following 
overlay with 3% carboxymethylcellulose, 
plates were incubated at 37°C and 5% CO2 
for 3-5 days. After fixation and staining, 
plaques in each well were counted and 
titers calculated using percentage 
reduction in plaques compared to the 
WNV control wells (50% reduction in 
number of plaques [PRNT50] was used as 
neutralizing end-point)19, 26. Human serum 
with titer of, at least, 1:10 was regarded as 
positive with protective anti-WNV 
antibodies. 
Data analysis: 
Results obtained were presented with 
descriptive statistics at 95% confidence 
interval (CI). In order to establish 
associations between study variables, 
Student’s t-test, Chi-square and binary 
logistic regression (BLR) analysis were 
used with statistical significance set at p  
0.05. The analyses were done using Excel 
spreadsheet and SPSS version 15.0 for 
Windows (SPSS Inc., Chicago, IL, USA).  
RESULTS: 
Study participants: 
A total of two hundred and thirteen (male 
and female) participants were studied. The 
overall age of the participants ranged from 
0.5-66.0 years (yrs), mean age was 31.8 
yrs [95% CI: 30.0-33.6]. Table 1 shows 
the distribution of the human participants 
involved in the study. Forty of the 82 
patients recruited in UCH had fever (  
38.3°C) as observed by the attending 
physician and they presented with various 
clinical signs/symptoms such as fever, 
headache, muscular/joint and abdominal 
pains. The remaining 42 patients from 
UCH were afebrile but had other clinical 
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 signs/symptoms that simulated malaria 
and or typhoid fever as stated above. A 
total of 136 study participants (5 from 
UCH, 106 from CMDC and 25 horse 
grooms) were apparently healthy. The 
remaining 77 participants, all from UCH, 
had pertinent clinical signs/symptoms.  
Malaria parasite test for detection of 
Plasmodium species: 
Out of the 188 blood samples (82 from 
UCH and 106 from CMDC) tested for 
malaria parasite, 63 tested positive for 
Plasmodium falciparum, giving an overall 
prevalence rate of 33.5% (95% CI: 26.8-
40.3). By location, 19 (23.2%, 95% CI: 
14.0-32.3) of the 82 participants from 
UCH were MP-positive with five of them 
having headache, fever and body pains to 
give 26.3% concordance between clinical 
signs/symptoms and laboratory diagnosis 
of malaria. In comparison, 44 of the 106 
humans screened at CMDC tested positive 
for MP to give a location-specific 
prevalence rate of 41.5% (95% CI: 32.1-
50.9).  
Widal slide agglutination assay  
A total of 188 participants were tested by 
the Widal slide agglutination test. The titer 
of positive sera for O antigens of S. typhi 
and paratyphi ranged from 1:80 to 1:320; 
for the H antigens however, it ranged from 
1:160 to 1:640. In all, 75 sera (39.9%, 95% 
CI: 32.4-46.9) had antibodies (agglutinins) 
indicative of typhoid fever. For location-
specific antibody prevalence, 30 of the 82 
participants from UCH were positive to
Table 1: Distribution of human participants in the study. 
Group Number of  
participants 
































a=significant difference in mean age 
give 36.6% [95% CI: 26.2-47.0]; 10 
(33.3%) of these had fever and abdominal 
discomfort/pains that simulated clinical 
typhoid, thereby showing concordance 
between clinical and laboratory diagnosis 
of the disease. Of the 106 participants 
from CMDC, 44 were positive for Widal 
test to give a prevalence rate of 41.5% 
[95% CI: 32.1-50.9]. 
WNV serology: 
Serologic assays were done for the 213 
individuals (82 from UCH, 106 from 
CMDC and 25 horse grooms from Lagos 
and Ibadan). A total of 156 humans had 
detectable WNV antibodies by ELISA, 
giving overall WNV IgG antibody 
prevalence of 73.2% [95% CI: 67.3-79.2]. 
The prevalence of WNV antibodies among 
the 188 subset (those from UCH and 
CMDC) was 75.5% [95% CI: 69.4-81.7]. 
The participants from UCH that were 
seropositive were 72, giving a location-
specific prevalence rate of 87.8% [95% CI: 
80.7-94.9] while in CMDC, 70 of the 106 
participants had WNV antibodies giving a 
prevalence rate of 66.0% [95% CI: 57.0-
75.1%]. Therefore, compared to the 
CMDC cohort, those from UCH, had 
significantly higher WNV antibody 
prevalence with p-value of 0.001 and odds 
ratio (OR) of 3.7 (95% CI: 1.7-8.0).  
Regarding clinical picture, group-specific 
prevalence rates showed that 36 of the 40 
febrile patients from UCH had WNV 
antibodies, to give prevalence rate of 
90.0% [95% CI: 80.7-99.3]. Of the 
remaining 42 non-febrile patients in UCH, 
35 (83.3%, 95% CI: 72.1-94.6) had WNV
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Table 2: Variables analyzed for association with WNV antibody positivity in humans 
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Figure 1: WNV antibody prevalence in relation to age of participants. 
antibodies. Comparison of the prevalence 
rates of the febrile and non-febrile patients 
showed they were statistically comparable 
(p = 0.38).   
Out of the 136 apparently healthy 
participants (106 from CMDC, 5 from 
UCH and 25 horse grooms) screened by 
MP and typhoid tests, 85 were positive for 
WNV antibodies giving a prevalence rate 
of 62.5% [95% CI: 54.4-70.6].  
The remaining 77 participants, all from 
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signs/symptoms; of these, 71 (92.2% [95% 
CI: 82.2-98.2]) were positive for WNV 
antibodies. Comparison of the prevalence 
rates of these two different clinical groups 
indicated association between clinical 
illness and WNV seropositivity (OR: 7.1 
[95% CI: 2.9-17.5], p = 0.001). 
In order to investigate differences in 
exposure to WNV by age group, the 
participants were divided into two: those  
17 yrs and 18-66 yrs. The former recorded 
47.4% seroprevalence (9/19, 95% CI: 
24.9-69.8%) while the latter gave 75.8% 
(147/194, 95% CI: 69.7-81.8%). Statistical 
analysis showed that the older age group 
had significantly higher (p = 0.008) WNV 
seroprevalence with OR of 3.5 compared 
to the  17 yrs age group.  
The participants were also divided into 
two groups to reflect propensity for 
outdoor activities which possibly exposed 
them to WNV mosquito vectors. The first 
group was the “non-active” participants in 
the age range 0.5-14 yrs and 56-66 yrs 
(n=24) who were more likely to be 
indoors. Fifteen of these (62.5%) had 
WNV antibodies. In the second group 
designated as “active” with participants 
aged 16-55 yrs, WNV seropositivity was 
74.6% (141/189); comparison of the two 
group-specific prevalence rates showed 
they were statistically comparable (p = 
0.21).  It was observed, however, that 
participants in the age range 0.5-14 yrs had 
50.0% (6/12) WNV antibody prevalence 
while those aged 56-66 yrs had 
seroprevalence of 75.0% (9/12). 
Among the 25 horse grooms who were all 
males, 14 (56.0%, 95% CI: 36.5-75.5) had 
WNV antibodies. Of the 12 from Eleyele 
Polo club, Ibadan, eight (66.7%) had 
WNV antibodies while six (46.2%) of the 
13 grooms in Lagos were seropositive. 
Comparison of WNV seroprevalence 
between the 25 grooms and the remaining 
188 participants showed that the latter had 
significantly higher seroprevalence with a 
p-value of 0.04 and OR of 2.4 (95% CI: 
1.0-5.7).  
Binary logistic regression and Chi-square 
analyses to establish associations between 
other participants’ variables and WNV 
antibody positivity are as shown in Table 
2. It was observed that WNV antibody 
prevalence rate significantly increased 
with increasing age of participants (Figure 
1). The results of PRNT on the human sera 
are shown in Table 3. 
Identification of participants with 
undifferentiated febrile illness: 
The analysis to establish contribution of 
WNV infection to undifferentiated febrile 
illness involved 188 participants (the 
patients in UCH and CMDC) that were 
tested for MP, typhoid and WNV 
antibodies. Only the participants from 
UCH, however, had clinical data. Overall, 
167 participants (88.8% [95% CI: 84.3-
93.3]) were positive for, at least, one of the 
three tests (Figure 2).  
It was observed that 24 participants 
(12.8%, [95% CI: 8.0-17.5%]) were 
positive while 21 (11.2%, [95% CI: 6.7-
15.7%]) were negative for all the three 
tests. Of the latter, only one participant 
(4.7%) was free of all the pertinent clinical 
signs/symptoms.  
A total of 58 persons (30.9%, [95% CI: 
24.2-37.5%]) were positive for only WNV 
antibody (Figure 2) with 40 of them being 
among the UCH cohort and having febrile 
illness (  38.3°C). Notably, 18 (45.0%, 
[95% CI: 29.6-60.4%]) of the 40 febrile 
patients tested positive for only WNV 
antibody (i.e. they were negative for both 
MP and Widal tests). These probably 
represented participants with condition 
described as “undifferentiated febrile 
illness”. Other various outcomes of the 
three tests are as shown in Figure 2. 
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Figure 2: Venn diagram showing inter-relationship between positive results for WNV 
antibody, MP and Widal tests. 
DISCUSSION: 
In order to establish exposure of humans 
(including horse grooms) in southwestern 
Nigeria to WNV and provide information 
on possible contribution of WNV to cases 
usually referred to as “undifferentiated 
febrile illness”, we studied sera of 213 
human participants. The observation that 
humans from UCH were significantly 
older in average age than either of the 
other two cohorts suggests that older 
participants were more likely to seek 
health care services in UCH (tertiary 
health institution) than younger ones. 
The overall anti-WNV antibody 
prevalence rate of 73.2%, though less than 
80.16% observed by Baba et al.14 in 
northern Nigeria, was still considerably 
high; the various group-specific 
prevalence rates were also high (Table 2). 
Control or elimination of infectious 
disease agents rests on protective 
immunity in a sufficient proportion of a 
given population of humans (or animals)27. 
Hence, in agreement with previous 
observation28, the high prevalence of 
WNV antibody in this study partly 
explains the absence of West Nile disease 
(WND) outbreaks in humans in 
southwestern Nigeria. Also, as earlier 
reported in humans and horses14, 22, 29, the 
high seroprevalence obtained is an 
indication of widespread or high WNV 
activity and endemicity in southwestern 
Nigeria. The high WNV seropositivity in 
this study could be partly explained by the 
location of Oyo, Lagos and surrounding 
states in the humid tropical rainforest 
region of Nigeria characterized by heavy 
rainfall and collection of water in peri-





















 = 21 
Sule & Oluwayelu Serologic Evidence of Exposure to WNV among Humans in Nigeria 
© Sudan JMS Vol. 11, No.3. Sept 2016                    119 
mosquito breeding30. In a similar study in 
Gabon42, a relatively high location-specific 
anti-WNV antibody prevalence rate 
(23.7%) was reported from the forested 
regions of the country. On the contrary, 
Baba et al.14 in the semi-arid zone of 
Nigeria reported high WNV IgG 
prevalence rate of 80.16% among febrile 
patients, which is slightly higher than the 
73.2% obtained in this study; they 
concluded that their study area was 
endemic for flavivirus.  
Though the group-specific WNV 
prevalence rates were generally high, the 
UCH participants had the highest 
prevalence rate with about 4 and 5 times 
higher likelihood of being WNV-
seropositive respectively compared to 
those from CMDC and the horse grooms 
(who were apparently healthy at the time 
of sampling). This could be due to the fact 
that majority of the UCH cohort (77 out of 
82) presented with one clinical 
sign/symptom or the other during 
sampling. Moreover, the analysis in this 
study has shown that being clinically ill 
was significantly associated with WNV 
seropositivity. Another possible reason 
could be that the study participants visiting 
UCH, a tertiary health care facility that 
receives patients from all parts of 
southwestern Nigeria as well as other 
states in Nigeria and beyond, had been 
exposed to WNV (or related flavivirus)-
infected mosquitoes in their various homes 
or neighbourhoods.  
Although the 106 participants from 
CMDC, which were mostly referral cases 
from Adeoyo State Hospital and other 
health care facilities in Oyo State, did not 
have clinical data and were all apparently 
healthy at the time of sampling, they also 
had high WNV seroprevalence rate. Thus, 
the WNV seroprevalence rates of the UCH 
and CMDC cohorts were statistically 
comparable, implying similar exposure of 
the participants to WNV. These high 
group-specific and overall WNV 
seroprevalence rates indicate endemicity 
of southwestern Nigeria for WNV.  
Apart from participants visiting health care 
facilities, 25 horse grooms that daily cared 
for horses were tested for presence of 
WNV antibody. Although more than half 
(14/25, 56.0%) of the grooms were 
positive for WNV antibodies, their 
seroprevalence was significantly lower 
compared to that of participants from UCH 
and CMDC (75.5%). This suggests that 
horse grooming may not constitute a 
significant risk factor for WNV infection 
in southwestern Nigeria although the 
observation could also be attributed to the 
smaller sample size of the grooms. In a 
previous report22, high (90.3%) WNV 
seroprevalence was detected in the horses 
cared for by grooms. Comparison of WNV 
seroprevalence rates, which is an indicator 
of exposure to WNV, in the two species 
revealed that the horses43 had significantly 
higher seroprevalence with 7 times 
likelihood (p = 0.001, OR = 7.0 [95% CI: 
2.7-18.0]) of being seropositive than their 
handlers. This shows that the horses were 
more exposed to WNV which could be an 
indication that the mosquito vectors had a 
biting/feeding preference for horses than 
their grooms, even though they live in the 
same environment. Additionally, the open 
stables of the horses could have exposed 
them more to mosquito vectors compared 
to the grooms who slept indoors at night. 
In a similar study of 1,280 sera from 80 
jockeys and grooms, 100 fowlers, 500 
blood donors, 600 healthcare workers, 100 
veterinary surgeons and 100 hunters in 
Italy, zero WNV seroprevalence was 
reported20. While this report from Italy 
might suggest that being around horses 
does not pose a significant risk of WNV 
infection, it is contrary to the findings of 
the current study in which WNV 
antibodies were detected in horse grooms. 
The WNV seropositivity obtained for 
Sule & Oluwayelu Serologic Evidence of Exposure to WNV among Humans in Nigeria 
© Sudan JMS Vol. 11, No.3. Sept 2016                    120 
horse grooms in the present study is 
probably due to endemicity of 
southwestern Nigeria for the virus and 
widespread activity of Culex mosquito 
vectors which have been reported to be 
abundant in the region43. 
It was observed that the 18-66 years old 
participants had significantly higher WNV 
seroprevalence and were about 4 times 
more likely to be positive than the  17 
year age-group. This suggests that the 
propensity for WNV infection increases 
with advancing human age and could be 
due to the tendency for the older 
individuals (“active” age group) to stay 
outdoors more than the  17 year old 
participants (“non-active” age group), 
which predisposes the former more to 
mosquito bites. These observations are 
similar to that of El Rhaffouli et al. 35 that 
young individuals who were more likely to 
stay outdoors for work or leisure (socio-
economic activities) had greater exposure 
to WNV vectors. In a previous study, Baba 
et al.14 attributed high rate of exposure to 
mosquito bites and subsequent WNV 
infection to large-scale tree planting in 
Borno State, Nigeria that provided shelter 
for mosquitoes and shade for human 
outdoor activities. Another plausible 
reason for the observation might be the 
endemicity of southwestern Nigeria for 
WNV as observed in this study and 
previous studies involving horses in the 
region22, 29. Moreover, the high 
seropositivity obtained for the older age-
group could partly explain the absence of 
West Nile disease in southwestern Nigeria 
as already reported28. The observation, 
however, that 78.9% of the seropositive 
individuals detected by ELISA were 
negative by PRNT may account for the 
absence of WND in the study area because 
these individuals might actually possess 
CF or HI antibodies or antibodies against 
related flaviviruses which, to a great 
extent, are also protective against WNV 
infection33. 
The fact that no significant difference in 
WNV antibody prevalence exists between 
the MP-positive and MP-negative groups 
(Table 2) suggests that although 
Plasmodium spp. and WNV are 
transmitted by mosquitoes, the vector 
species of these two infectious agents are 
different and they both cause disease 
independent of each other in their human 
hosts. This is corroborated by previous 
reports showing that malaria is transmitted 
majorly by Anopheles mosquitoes and 
WNV by Culex species44,45. Similarly, the 
comparable WNV antibody prevalence 
rates obtained for the Widal test-positive 
and -negative individuals in this study 
shows that presence of typhoid fever is not 
associated with WNV seropositivity.   
With respect to protective WNV 
neutralizing antibody, the fact that 
majority (89.5%) of the sera tested by 
PRNT were negative even when 78.9% 
were ELISA-positive suggests that the 
participants were likely exposed to other 
antigenically related flaviviruses. It could 
also be that the antibodies were actually 
specific for WNV but non-neutralizing 
(probably complement fixing or 
haemagglutination-inhibiting). 
Interestingly, one serum sample that was 
negative for WNV antibodies by cELISA 
was not only positive by PRNT, it had a 
protective titer of 1:1019 (Table 3). Since 
PRNT is a highly specific assay, it can be 
inferred that the individual was certainly 
exposed to WNV and that PRNT also has 
considerable sensitivity for detection of 
WNV antibodies. This study has shown 
that none of the sera tested by real-time 
RT-PCR contained WNV RNA (evidence 
of viraemia), indicating that none of the 
participants’ had ongoing WNV infection 
at the time of sampling. Though herd 
immunity  against  WNV  has  not  been 
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established in any animal species, the high 
WNV antibody prevalence rate among the 
participants in this study was probably 
responsible for clearance of the viraemia 
prior to sampling36, 37. Wang et al.38 made 
similar observation of no WNV RNA in 
human sera. The only recent study similar 
to this in southwestern Nigeria is the study 
by Opaleye et al.39 in which none of the 
185 blood donors tested in Osun state had 
detectable WNV-IgM. In northern Mexico, 
Rodr guez et al.33 also reported that out of 
588 febrile individuals, 44 encephalitic 
patients and 800 asymptomatic blood 
donors, none had detectable WNV-IgM. 
Since IgM is known to persist in human 
blood for about 2-3 months to more than a 
year40, its non-detection in this study 
despite the presence of WNV-IgG 
indicates that exposure of the WNV 
antibody-positive humans had occurred, at 
least, more than three months prior to 
sampling. 
The observation that 88.8% of the 188 
participants (excluding the horse grooms) 
analysed were positive for, at least, one of 
the three pathogens (Plasmodiun
falciparum, Salmonella typhi or paratyphi 
A, B and C, and WNV antibody) was not 
unexpected as Nigeria is known to be 
endemic for malaria and typhoid fevers15, 
21. Likewise, the observed high WNV 
seropositivity has established southwestern 
Nigeria as being endemic for WNV and 
this is further buttressed by previous 
observation that WNV was enzootic 
among horses in the same area22.  
Also, the finding that clinically ill 
participants were about 7 times (OR: 7.1, p 
= 0.001) more likely to be WNV 
seropositive than the apparently healthy 
ones shows that, although southwestern 
Nigeria is endemic for malaria and typhoid 
fever, clinical illness presenting with fever 
and other relevant signs/symptoms in 
health care facilities could likely be due to 
WNV or  antigenically related flaviviruses 
such as yellow fever or dengue that are 
rarely considered during diagnosis of 
febrile conditions in the country; most 
health care centres lack the facilities and 
trained personnel to investigate arboviral 
causes of fever. Additionally, the fact that 
participants had greater odds of being 
positive for WNV antibodies compared to 
MP and Widal tests showed that they were 
mostly exposed to WNV or a related 
flavivirus. The results presented in Figure 
2 further corroborate greater exposure of 
the participants to WNV as those  positive 
for WNV antibody alone were about six 
times more than those positive for only 
MP or typhoid test. These findings 
underscore the need to consider WNV 
when patients present with 
fever/headache/body pains at health care 
facilities in southwestern Nigeria. Some 
limitations of this study are that 
information on the yellow fever 
vaccination status of the participants was 
not collected, while the sera were also not 
tested for antibodies to endemic yellow 
fever and dengue viruses. These would 
have, revealed possible cross-reactivity of 
the tested sera with WNV.   
It is noteworthy that of the 40 participants 
from UCH with fever, 18 (45.0%) were 
seropositive for only WNV. This sub-
population could therefore be described as 
individuals with undifferentiated febrile 
illness as previously reported15, 41. This 
observation is buttressed by the fact that 
significant association (p = 0.001) existed 
between being clinically ill and WNV 
antibody positivity in the present study.  
In conclusion, this study revealed that 
humans in southwestern Nigeria had 
serologic evidence of exposure to WNV, 
even though none of the tested sera had 
evidence of viraemia. The high 
seroprevalence of WNV antibodies 
obtained is an indication of endemicity of 
southwestern Nigeria for WNV. 
Additionally, the observation that many of 
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the tested humans had no 
protective/neutralizing antibodies against 
WNV, even when they were positive for 
WNV antibodies by cELISA, suggests 
serologic cross-reactivity with 
antigenically related flaviviruses or that 
the WNV antibodies detected were non-
neutralizing. The study participants were 
mostly exposed to WNV than either 
Plasmodium spp or S. typhi/paratyphi. 
Moreover, the high prevalence of 
antibodies against WNV or related 
flaviviruses could account for the absence 
of West Nile neurologic disease among 
humans in the study area. Finally, WNV 
infection accounted for about half (45.0%) 
of the cases of undifferentiated febrile 
illness among the participants involved in 
this study while humans of “active” and 
“non-active” age groups had similar 
exposure to WNV.  
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